Gary C.W. Chan

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis

Desmond Y. H. Yap, Colin Tang, Gary C.W. Chan et al. · The Journal of Rheumatology · 2018 · 67 citations · Full text

Long-term data on tacrolimus treatment in lupus nephritis

Desmond Y. H. Yap, K. M. Maggie, Maggie M.Y. Mok et al. · Lara D. Veeken · 2014 · 58 citations

Cancer Incidence and Mortality in Chronic Dialysis Population: A Multicenter Cohort Study

Chi Yuen Cheung, Gary C.W. Chan, Siu Kim Chan et al. · American Journal of Nephrology · 2016 · 58 citations · Full text